156 related articles for article (PubMed ID: 36989844)
1. Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells.
Watanabe H; Fujishima F; Unno M; Sasano H; Suzuki T
Pathol Res Pract; 2023 Apr; 244():154418. PubMed ID: 36989844
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors.
Watanabe H; Fujishima F; Komoto I; Imamura M; Hijioka S; Hara K; Yatabe Y; Kudo A; Masui T; Tsuchikawa T; Sakamoto K; Shiga H; Nakamura T; Nakaya N; Motoi F; Unno M; Sasano H
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159042
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.
Kim JY; Kim J; Kim YI; Yang DH; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
Sci Rep; 2024 Feb; 14(1):4047. PubMed ID: 38374188
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
[TBL] [Abstract][Full Text] [Related]
5. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
7. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
8. Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors.
Fotouhi O; Zedenius J; Höög A; Juhlin CC
Neuro Endocrinol Lett; 2018 Oct; 39(4):305-309. PubMed ID: 30531706
[TBL] [Abstract][Full Text] [Related]
9. Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells.
Jo H; Park Y; Kim J; Kwon H; Kim T; Lee J; Pyun JC; Lee M; Yun M
PLoS One; 2020; 15(10):e0240107. PubMed ID: 33045023
[TBL] [Abstract][Full Text] [Related]
10. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
11. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.
Qian ZR; Li T; Ter-Minassian M; Yang J; Chan JA; Brais LK; Masugi Y; Thiaglingam A; Brooks N; Nishihara R; Bonnemarie M; Masuda A; Inamura K; Kim SA; Mima K; Sukawa Y; Dou R; Lin X; Christiani DC; Schmidlin F; Fuchs CS; Mahmood U; Ogino S; Kulke MH
Pancreas; 2016 Nov; 45(10):1386-1393. PubMed ID: 27622342
[TBL] [Abstract][Full Text] [Related]
12. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.
Sherman SK; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
Surgery; 2013 Dec; 154(6):1206-13; discussion 1214. PubMed ID: 24238043
[TBL] [Abstract][Full Text] [Related]
13. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer.
Klomp MJ; Dalm SU; de Jong M; Feelders RA; Hofland J; Hofland LJ
Rev Endocr Metab Disord; 2021 Sep; 22(3):495-510. PubMed ID: 33085037
[TBL] [Abstract][Full Text] [Related]
15. GIPR expression in gastric and duodenal neuroendocrine tumors.
Sherman SK; Maxwell JE; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
J Surg Res; 2014 Aug; 190(2):587-93. PubMed ID: 24565507
[TBL] [Abstract][Full Text] [Related]
16. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
Pisarek H; Pawlikowski M; Kunert-Radek J; Kubiak R; Winczyk K
Folia Histochem Cytobiol; 2010 Jan; 48(1):142-7. PubMed ID: 20529830
[TBL] [Abstract][Full Text] [Related]
17. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
18. Role of Somatostatin Signalling in Neuroendocrine Tumours.
Rogoza O; Megnis K; Kudrjavceva M; Gerina-Berzina A; Rovite V
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163374
[TBL] [Abstract][Full Text] [Related]
19. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5.
Popa O; Taban SM; Pantea S; Plopeanu AD; Barna RA; Cornianu M; Pascu AA; Dema ALC
Exp Ther Med; 2021 Oct; 22(4):1179. PubMed ID: 34475969
[TBL] [Abstract][Full Text] [Related]
20. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
